articleTop 1% cited
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
The Lancet Oncology · 2014 · Vol. 16(1) · pp. 25–35
Richard S. Finn(University of California, Los Angeles)John Crown(Cancer Trials Ireland)István Láng(National Institute of Criminology)Katalin Boér(Szent János Kórház)Igor Bondarenko(Dnipropetrovsk State Medical Academy)Sergey O. KulykJohannes Ettl(Technical University of Munich)Ravindranath Patel(Comprehensive Blood & Cancer Center)Tamás Pintér(Petz Aladár Megyei Oktató Kórház)Marcus Schmidt(Johannes Gutenberg University Mainz)Yaroslav Shparyk(Lviv National Musical Academy named after Mykola Lysenko)Anu Thummala(Comprehensive Cancer Centers of Nevada)Nataliya L. Voytko(Kyiv City Clinical Oncology Center)Camilla Fowst(Pfizer (Italy))Xin Huang(Pfizer (United States))Sindy T. Kim(Pfizer (United States))Sophia Randolph(Pfizer (United States))Dennis J. Slamon✉(University of California, Los Angeles)
Advanced Breast Cancer TherapiesBreast Cancer Treatment StudiesHER2/EGFR in Cancer ResearchPalbociclibLetrozoleMedicineOncologyBreast cancerInternal medicineClinical endpointPopulationCohortCancer
MeSH terms
LetrozoleAdministration, OralAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsDrug Administration ScheduleEuropeFemaleHumansMiddle AgedNitrilesNorth AmericaPiperazinesPyridinesReceptors, Estrogen
Funding
- U.S. Department of Defense
Citations
1,891
FWCI
134.48
field-weighted impact
References
23
Percentile
100%
vs. same field & year
Citations per year
Cited by
Assessing health-related quality of life (QOL) of Palbociclib plus endocrine therapy in Iraqi patients with metastatic breast cancer
International journal of oncology research. · 2025 · 0 citations
Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma
Cells · 2020 · 484 citations
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
Drugs · 2020 · 404 citations
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Annals of Oncology · 2018 · 1,168 citations
The history and future of targeting cyclin-dependent kinases in cancer therapy
Nature Reviews Drug Discovery · 2015 · 1,738 citations
Endocrine resistance in breast cancer – An overview and update
Molecular and Cellular Endocrinology · 2015 · 351 citations
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Annals of Oncology · 2016 · 2,058 citations
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
The Lancet Oncology · 2016 · 1,795 citations
References
Proportional hazards tests and diagnostics based on weighted residuals
Biometrika · 1994 · 5,490 citations
Cell cycle, CDKs and cancer: a changing paradigm
Nature reviews. Cancer · 2009 · 3,885 citations
Comprehensive molecular portraits of human breast tumours
Nature · 2012 · 12,217 citations
Molecular portraits of human breast tumours
Nature · 2000 · 16,173 citations
Global cancer statistics
CA A Cancer Journal for Clinicians · 2011 · 55,006 citations
Hallmarks of Cancer: The Next Generation
Cell · 2011 · 65,668 citations
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
New England Journal of Medicine · 2001 · 11,439 citations
Related articles
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
Breast Cancer Research and Treatment · 2019 · 426 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.